“Fixer-Upper” Encysive’s Thelin Is Pfizer’s Problem Now
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma knight rescues Encysive, with its troubled Thelin for pulmonary hypertension, in a deal worth about $200 million.